|1|Protective effects of endothelin receptor A and B inhibitors against doxorubicin-induced cardiomyopathy. (25660617)
Schwebe M.... Bien-MAPller S.
|2|Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. (25569804)
Hao E.... Pacher P.
|3|A metabolomic study of rats with doxorubicin-induced cardiomyopathy and Shengmai injection treatment. (25938766)
Chen Y.... Xiang Y.
|4|Potent Paracrine Effects of human induced Pluripotent Stem Cell-derived Mesenchymal Stem Cells Attenuate Doxorubicin-induced Cardiomyopathy. (26057572)
Zhang Y.... Lian Q.
|5|Protective effect of cilostazol against doxorubicin-induced cardiomyopathy in mice. (26191652)
Koh J.S.... Roh G.S.
|6|Heart rate dynamics in doxorubicin-induced cardiomyopathy. (25798626)
LonA8ar-Turukalo T.... JapunA3iA8-A1igon N.
|7|Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy. (26511374)
Chen Y.L.... Yip H.K.
|8|Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism. (24486195)
Andreadou I.... Iliodromitis E.K.
|9|Interrelation between Expression of ADAM 10 and MMP 9 and Synthesis of Peroxynitrite in Doxorubicin Induced Cardiomyopathy. (24244825)
|10|Manipulation of Cardiac PI3K/Akt Signaling by Apoptosis regulator through modulating IAP expression (ARIA) Regulates Cardiomyocyte Death during the Doxorubicin-induced Cardiomyopathy. (24338479)
Kitamura Y.... Ikeda K.
|11|Antioxidant, lipid lowering, and membrane stabilization effect of sesamol against doxorubicin-induced cardiomyopathy in experimental rats. (24228260)
Chennuru A.... Saleem M.T.
|12|Increased beta2-adrenoceptors in doxorubicin-induced cardiomyopathy in rat. (23741376)
Merlet N.... Gauthier C.
|13|Embryonic stem cells improve cardiac function in Doxorubicin-induced cardiomyopathy mediated through multiple mechanisms. (22449713)
Singla D.K.... Yan B.
|14|Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. (22465037)
Octavia Y.... Moens A.L.
|15|Discordant impairment of multidirectional myocardial deformation in rats with Doxorubicin induced cardiomyopathy. (22486544)
Kim Y.H.... Shim W.J.
|16|Inorganic nitrate therapy improves Doxorubicin-induced cardiomyopathy a new window for an affordable cardiovascular therapy for everyone? (21596235)
Daiber A.... MA1nzel T.
|17|Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation ofA mitochondrial function. (21094500)
Hiona A.... Wu J.C.
|18|Potential biomarkers in mouse myocardium of doxorubicin-induced cardiomyopathy: a metabonomic method and its application. (22110719)
Tan G.... Chai Y.
|19|Thrombopoietin protects against doxorubicin-induced cardiomyopathy, improves cardiac function, and reversely alters specific signalling networks. (21330293)
Chan K.Y.... Sung R.Y.
|20|Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy. (21946105)
Campos E.C.... Rossi M.A.
|21|S-diclofenac protects against doxorubicin-induced cardiomyopathy in mice via ameliorating cardiac gap junction remodeling. (22039489)
Zhang H.... Wang C.
|22|Diclofenac sodium, a nonselective nonsteroidal anti-inflammatory drug aggravates doxorubicin-induced cardiomyopathy in rats. (19920767)
Singh B.K.... Dubey K.
|23|Involvement of advanced glycation end-products, pentosidine and N(epsilon)-(carboxymethyl)lysine, in doxorubicin-induced cardiomyopathy in rats. (20004697)
Moriyama T.... Horie T.
|24|Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. (20543097)
Koka S.... Kukreja R.C.
|25|How to protect doxorubicin-induced cardiomyopathy in male albino rats? (20051877)
Shaker O.... Sourour D.A.
|26|CO liberated from a carbon monoxide-releasing molecule exerts a positive inotropic effect in doxorubicin-induced cardiomyopathy. (19935076)
Musameh M.D.... Fuller B.J.
|27|CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. (19942623)
Mukhopadhyay P.... Pacher P.
|28|Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. (19010377)
Martin E.... Jensen L.H.
|29|Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model. (18379782)
Xiang P.... Sung R.Y.
|30|Treatment with an adenoviral vector encoding hepatocyte growth factor mitigates established cardiac dysfunction in doxorubicin-induced cardiomyopathy. (18083897)
Esaki M.... Fujiwara H.
|31|Granulocyte colony-stimulating factor improves left ventricular function of doxorubicin-induced cardiomyopathy. (17334414)
Li L.... Fujiwara H.
|32|Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. (16449733)
Li L.... Fujiwara H.
|33|Overexpression of Nd1, a novel Kelch family protein, in the heart of transgenic mice protects against doxorubicin-induced cardiomyopathy. (16952015)
Matsudo Y.... Hatano M.
|34|Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy. (16039240)
Simsir S.A.... Milano C.A.
|35|Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. (16364871)
Tallaj J.A.... Bourge R.C.
|36|Anti-oxidants and apoptosis: attenuation of doxorubicin induced cardiomyopathy by carvedilol. (15380672)
|37|Mechanical unloading improves intracellular Ca2+ regulation in rats with doxorubicin-induced cardiomyopathy. (15582323)
Takaseya T.... Aoyagi S.
|38|Molecular biology of doxorubicin-induced cardiomyopathy. (19644577)
Umlauf J.... HorkA1 M.
|39|Doxorubicin-induced cardiomyopathy during pregnancy: three case reports of anesthetic management for cesarean and vaginal delivery in two kyphoscoliotic patients. (12151947)
Pan P.H.... Moore C.H.
|40|Doxorubicin-induced cardiomyopathy. (10910374)
Otero F.J.... Sheahan R.G.
|41|Evaluation of cardiac adrenergic neuronal damage in rats with doxorubicin-induced cardiomyopathy using iodine-131 MIBG autoradiography and PGP 9.5 immunohistochemistry. (10901455)
Jeon T.J.... Cho S.H.
|42|Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. (10503942)
Matsui H.... Hayakawa T.
|43|Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. (9848575)
Noda T.... Suzuki T.
|44|Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. (9038198)
Jeyaseelan R.... Kedes L.
|45|Contractile failure in chronic doxorubicin-induced cardiomyopathy. (9344758)
Boucek R.J.... Olson R.D.
|46|Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin. (7831179)
Sriskandan S.... Gore M.E.
|47|Etiology of sarcoplasmic reticulum calcium release channel lesions in doxorubicin-induced cardiomyopathy. (1314436)
Pessah I.N.... Giri S.N.
|48|Case presentation of doxorubicin-induced cardiomyopathy: a short- and long-term side effect of pediatric cancer treatment. (1675089)
|49|Activity of receptors coupled to guanine nucleotide binding regulatory protein in doxorubicin induced cardiomyopathy. (1660348)
Fu L.X.... Hjalmarson A.
|50|Diminishment of respiratory sinus arrhythmia foreshadows doxorubicin-induced cardiomyopathy. (1860214)
Hrushesky W.J.... Cope F.O.